-
Mashup Score: 3
With the Oncology Brothers, Uma Borate, MD, discusses how CPX-351 demonstrates superior efficacy over 7+3 chemotherapy in treating acute myeloid leukemia with mutations in measurable residual disease (AML-MR) by specifically targeting the genetic mutations driving the disease, leading to improved patient outcomes.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2HT-6184 Advances to Second Stage of Phase 2 Trial in LR-MDS - 19 hour(s) ago
Positive topline data from a phase 2 trial show HT-6184, an allosteric NEK7/NLRP3 inflammasome inhibitor, improves hematologic response in lower-risk MDS.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
Positive topline data from a phase 2 trial show HT-6184, an allosteric NEK7/NLRP3 inflammasome inhibitor, improves hematologic response in lower-risk #MDS. #mpnsm https://t.co/GSB7ZvWrSu
-
-
Mashup Score: 2ELEVATE Study: Design - 2 day(s) ago
Hope S. Rugo, MD, FASCO, discusses how the phase 3 ELEVATE study evaluates the combination of elacestrant with abemaciclib in patients with ER+/HER2– advanced or MBC who have progressed on prior endocrine therapy.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
In this video, @hoperugo discusses how the phase 3 ELEVATE study evaluates the combination of elacestrant with abemaciclib in patients with ER+/HER2– advanced or MBC who have progressed on prior endocrine therapy. #bcsm https://t.co/XZ0Rw44cSM
-
-
Mashup Score: 2
Joe Leach, MD, discusses how comprehensive biomarker testing has impacted treatment selection for patients with small cell lung cancer.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
WATCH: Joe Leach, MD, discusses how comprehensive biomarker testing has impacted treatment selection for patients with small cell lung cancer. #SCLC #lcsm https://t.co/tCBIlIaxwn
-
-
Mashup Score: 12Fellow's Perspective: Impact of Quadruplet and MRD in Newly Diagnosed Multiple Myeloma - 2 day(s) ago
In a discussion with Peers & Perspectives in Oncology, fellowship program director Marc J. Braunstein, MD, PhD, FACP, and hematology/oncology fellow Olivia Main, MD, talk about how recent trials shape their approach for a patient with transplant-eligible multiple myeloma.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
Marc J. Braunstein, MD, PhD, FACP, (@docbraunstein) and hematology/oncology fellow Olivia Main, MD, talk about how recent trials shape their approach for a patient with transplant-eligible multiple myeloma. #mmsm | @Perlmutter_CC @NYULISOM_HemOnc https://t.co/XcZIluizO1 https://t.co/vsZ1RPfSoC
-
-
Mashup Score: 2Introduction to the Discussion of Frontline Treatment for Newly Diagnosed Lower-Risk Myelodysplastic Syndromes. - 2 day(s) ago
Following a recent update in to NCCN gGuidelines, Drs. Garcia- Manero and Swoboda introduce themselves and theirwill discussion about the changing landscape of lower-risk myelodysplastic syndromeLR-MDS treatment.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
Introduction to the Discussion of Frontline Treatment for Newly Diagnosed Lower-Risk Myelodysplastic Syndromes. #MDS @MdSwoboda https://t.co/uJKNbRAtHT
-
-
Mashup Score: 3
With the Oncology Brothers, Uma Borate, MD, discusses how ziftomenib is showing promising results as a targeted therapy for NPM1-mutated and KMT2A-rearranged acute myeloid leukemia (AML) in the ongoing KOMET-007 trial, offering potential new treatment options for this challenging patient population.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
With the Oncology Brothers (@OncBrothers), Uma Borate, MD, (@beatalleukemia) discusses how ziftomenib is showing promising results as a targeted therapy for NPM1-mutated and KMT2A-rearranged #AML in the ongoing KOMET-007 trial. #leusm https://t.co/nqVEwd0wVr
-
-
Mashup Score: 2
During a Case-Based Roundtable® event, Daniel A. Ermann, MD, discussed evaluation and treatment for a patient with relapsed chronic lymphocytic leukemia after receiving venetoclax and obinutuzumab.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
Daniel A. Ermann, MD, discussed evaluation and treatment for a patient with relapsed chronic lymphocytic leukemia after receiving venetoclax and obinutuzumab. #CLL #leusm https://t.co/zoVtO5mbC2 https://t.co/KFzKczMg3K
-
-
Mashup Score: 2
Anita D’Souza, MD, discusses an abstract looking at the combination of teclistamab-cqyv, daratumumab, and pomalidomide in 2 phase studies for patients with multiple myeloma.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
WATCH: Anita D'Souza, MD, discusses an abstract looking at the combination of teclistamab, daratumumab, and pomalidomide in 2 phase studies for patients with multiple myeloma. #mmsm #ASH24 | @adsouza_md https://t.co/gFaxbGab5M
-
-
Mashup Score: 2
During a Case-Based Roundtable® event, Omar Nadeem, MD, and participants discussed managing toxicities of talquetamab in the second article of a 2-part series.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
Omar Nadeem, MD, (@OmarNadeemMD) and participants discussed managing toxicities of talquetamab. #MMSM | @DanaFarber @harvardmed https://t.co/aWwNZ5XMAt
-
The @OncBrothers and @beatalleukemia discuss how CPX-351 demonstrates superior efficacy over 7+3 chemotherapy in treating AML-MR by specifically targeting the genetic mutations driving the disease, leading to improved patient outcomes. #leusm https://t.co/ZYKCSzNhSJ